Accumulating evidence indicates that the interplay between host immune system and the tumor may have an impact on clinical outcome. [1] [2] [3] [4] Recently, Spisek et al. 5 described specific adaptive immune responses towards the embryonal stem cellassociated antigen SOX2 in patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor lesion to multiple myeloma (MM). Moreover, in a prospective study the authors were able to demonstrate a significantly better progression-free survival in MGUS patients with detectable anti-SOX2 T cell immunity. 5 The biological significance of iLRP in embryonal development is related to its induction of maternal anti-iLRP immunoglobulins and the activation of cytotoxic T cells which might protect the pregnant mother against lethal neoplasms formed by embryonic cells which escape the placental barrier. In term fetus, neonate, or normal adult differentiated tissues OFA-iLRP expression was not detected on the cell surface. 6, 7 In contrast, OFA/iLR is re-expressed on a broad range of malignancies including some hematological tumor entities. [8] [9] [10] By utilizing a mouse anti-OFA/iLR monoclonal antibody (Dr J Coggin, Mobile, Al, USA) we show that OFA/iLR is frequently expressed on the surface of malignant plasma cells of patients with MGUS, MM and plasma cell leukemia (Figures 1a and b) . For immunohistochemical staining Letters to the Editor and flow cytometry analysis goat anti-mouse immunoglobulin as a secondary antibody coupled to alkaline phosphatase (panel a) or to FITC (panels b and c) was used. Normal plasma cells from healthy volunteers were iLR-negative (panel c). For the analysis of specific anti-OFA/iLR antibodies a standard enzyme-linked immunosorbent assay (ELISA) was performed. Purified OFA/iLR (6 mg/ml) and HIVp24 (1 mg/ml, negative control) were bound to ELISA plates. Responses against HIVp24 (all patients negative) were used as a negative control and nonspecific reactivity was subtracted from each OFA/iLR optical density (OD) value. OFA/ILR protein was generated using a fulllength cDNA of OFA/iLRP cloned into an expression vector under the control of the tac promoter and expressed in Escherichia coli. 11 As shown in panels 1d and e, we found significant levels of anti-OFA/iLR antibodies in 21 of 30 sera of MGUS patients (70%) and seven of 27 (26%) patients with asymptomatic MM (AMM). In contrast, in sera from patients with progressive MM (n ¼ 67) and in normal healthy donors (HD, n ¼ 60) no humoral reactivity against OFA/iLR was present (panels d and e).
All patient sera with significant anti-OFA/iLR antibody levels were included in an epitope-mapping assay to confirm epitope Letters to the Editor specificity. A set of 42 synthetic peptides (OFA ) with a length of 17 amino acids (aa) overlapping by five aa and representing the entire sequence of OFA/iLR protein were used in a IgG and IgM ELISA. With regard to the localization of functional domains of OFA/iLR, the distribution of specific IgG and IgM responses includes association with intracellular as well as extracellular located epitopes (data not shown).
To look on long-term persistence of humoral anti-OFA/iLR immune responses, we were able to detect significant and stable titers of anti-OFA/iLR-specific IgG antibodies in follow-up samples of MGUS patients (n ¼ 6, panel f). IgG subclass analyses showed a predominant IgG1 and IgG3 response suggestive for a Th1-driven immune response in the vast majority of patients with MGUS and to smaller extent in patients with AMM (panel g).
To validate the specificity of the detected anti-OFA/iLR antibodies, an inhibition assay was performed in the presence of recombinant OFA/iLR protein, which was formerly used as a coating antigen in the ELISA. As depicted in panel l, reactivity to OFA/iLR of respective patient sera was inhibited by addition of the OFA/iLR protein in a dose-dependent manner. Utilizing OFA/iLR-reactive sera as a source of primary antibody and a FITC-conjugated secondary antibody in FACS analysis, CD138 þ purified plasma cells from an MGUS patient were recognized (panel k) whereas OFA/iLR-nonreactive sera from healthy donors did not bind to malignant plasma cells (panel j). More interestingly, patient derived anti-OFA/iLR antibodies were capable of selectively recognizing and killing OFA/iLR-expressing myeloma cells in complement-mediated and antibodydependent cellular cytotoxicity assays (panels h and i). Plasma cells from healthy donors were not significantly attacked. To determine whether the presence of anti-OFA/iLR antibodies influenced progression-free survival, patients were retrospectively analyzed according to the presence/absence of a humoral immune response against OFA/iLR protein. In a univariate analysis, the group of patients with reactive sera (n ¼ 28) showed a significantly lower probability of disease progression compared to patients with non-reactive sera (n ¼ 29). In the patient group with significant anti-OFA/iLR titers only two of 28 patients developed disease progression, but 18 of 29 patients with OFA/iLR non-reactive sera (P ¼ 0.001, panel m). In the cohort with detectable iLR reactive antibodies, there are 21 patients with MGUS and seven with AMM. Two of the seven AMM patients developed progressive disease. The recently published WHO 2008 criteria for Ph-myeloproliferative disorders (MPD) 1 have, in the opinion of the Czech MPD Working Group, several pitfalls.
James et al. 2 and many groups thereafter have suggested that JAK2 V617F mutation and increased values of the red blood cell parameters (or possibly, increased total red cell mass) suffice for the diagnosis of polycythemia vera (PV). However, the WHO criteria 1 introduce additional 'minor' criteria: (a) histopathology; (b) erythropoietin (Epo) values and (c) endogenous erythroid colony formation (EEC). In JAK2 mutated cases, one minor criterion is demanded, and in unmutated cases, two of them. The authors 1 advocate fulfilling the minor criteria as they fear of false JAK2 V617F positivity. However, if allelic discrimination assays are employed, this is extremely unlikely to happen: a discordant result was obtained in 0/261 samples screened by two alternative tests. 3 The minor criteria (b) and (c) may not be met at least in the early stages of PVFat this stage, Epo is quite frequently within the lower normal range and the EEC assay may be unavailable or falsely negative as it is technically rather difficult to perform (in the lab of one of us, EEC growth was demonstrated in only 79% of otherwise typical JAK2 V617F -positive MPDs; unpublished). In case, when two of the minor criteria (Epo and EEC) are missed, performing the (otherwise unnecessary) biopsy would be mandatory. However, the histological distinction of PV from essential thrombocythemia (ET) on the one hand and from primary myelofibrosis (PMF) on the other is sometimes not easy even for an experienced pathologist. Conversely, two minor criteria (Epo and EEC) may be occassionally met in cases of JAK2
V617F
-negative idiopathic erythrocytosis. 1 One of the major criteria of the WHO 2008 for PV is the presence of JAK2 V617F or JAK2 exon 12 mutation. 1 This may lead to substantial overlap and diagnostic confusion of the different entities, that is, true JAK2 V617F -positive PV and idiopathic erythrocytosis with JAK2 exon 12 mutation. Moreover, the cases with exon 12 mutation (as the major criterion 1 ) cannot be confirmed by histopathology (a minor criterion 1 ) because in cases with exon 12 mutation, the picture is far different from the typical PV 'panmyelosis'. 4 We would prefer omitting the minor criteria whatsoever. The risk of 'false' negativity of the minor criteria (lack of both elevated Epo and EEC growth) by far overweights the possibility of an erroneous JAK2 V617F result. We agree with the authors 1
